Document:

EXHIBIT 10.1

                              CONSULTING AGREEMENT
                          WITH BIG SKY MANAGEMENT LTD.

Date: March 21, 2002                                                CONFIDENTIAL

STRATABID.COM, INC.
1675 LARCH STREET
VANCOUVER, BC
V3K 3N7

Attention: Derek Wasson

Dear Sirs:

Re: Consulting Agreement

This letter  agreement  (the  "Agreement")  sets forth the terms and  conditions
under which Stratabid.com,  Inc. (the "Company") has retained Big Sky Management
Ltd.  ("Big Sky") to serve as the Company's  financial  consultant in connection
with the Company's organization and financing.

Duties of the Consultant

1.       Big Sky will assist the Company in effecting the Company's organization
         and financing on terms  acceptable to the Company.  In this regard,  we
         propose to undertake certain activities, including, if appropriate, the
         following:

         (a) assisting  the Company in preparing and refining its business plan;

         (b) identifying,  introducing  to,  and  consulting  as to strategy for
             initiating discussions with, potential investors; and

         (c) assisting in the preparation and review of definitive documentation
             in connection  with the Company's  organization  and  financing and
             coordinating  same with your legal counsel and accountants.

2.       It is  acknowledged  by the Company that neither Big Sky nor any of its
         representatives  are  registered  with or  licensed  by any  securities
         commission  or like  authority  as an  underwriter,  broker,  dealer or
         financial  advisor  and that the  services to be provided by Big Sky to
         the  Company  hereunder  shall  expressly  not  include  trading in the
         Company's  securities (either as principal or agent),  participating in
         an  offering  of the  Company's  securities  which is not  exempted  or
         otherwise in compliance with the requirements of applicable  securities
         laws,  or  engaging  in or  professing  to  engage in the  business  of
         advising  others with  respect to a purchase  or sale of the  Company's
         securities.

                                        1
                                                                    EXHIBIT 10.1
<PAGE>
Consulting Fee

3.       Subject to  section 4 hereof,  Big Sky's  compensation  for its role as
         financial  consultant  will be the sum of  US$1500  per month  plus GST
         payable of $105 (the  "Consulting  Fee"). Big Sky and the Company agree
         that the Consulting  Fee shall be payable to Big Sky, in arrears,  from
         the date of March 1st 2002 and on the 1st day of each month thereafter.

Termination

4.       This agreement has no set term of engagement and can be terminated with
         30 days notice by either  party.  It is expressly  understood  that the
         provisions  relating to the payment for the Expenses and the provisions
         of the  Indemnification  Agreement (as those terms are defined  herein)
         will survive  termination  of this  Agreement or the  completion of Big
         Sky's services hereunder.

Expenses

5.       In addition to the foregoing fees the Company agrees, upon request from
         time to  time,  to  promptly  reimburse  Big Sky for all  out-of-pocket
         expenses,  including,  but not  limited  to,  such  costs as  printing,
         telephone, fax, courier service, copying, accommodations and travel and
         direct computer expenses, and secretarial overtime ("Expenses").

Provision of Information and Indemnification Agreement

6.       In connection with Big Sky's engagement, the Company and its directors,
         officers,  employees,  representatives  and agents will furnish Big Sky
         with all data,  material,  and information  concerning the Company (the
         "Information") which Big Sky reasonably requests,  all of which will be
         accurate and complete in all material  respects at the time  furnished.
         The Company  recognizes and confirms that in undertaking the engagement
         contemplated  hereby, Big Sky will be using and relying  exclusively on
         the   Information   provided   by  the  Company   without   independent
         verification  and without  performing  any  appraisal  of the assets or
         businesses  of the  Company.  Big Sky is hereby  authorized  to use and
         deliver the  Information,  and any other data  obtained by Big Sky from
         reliable published  sources,  in accordance with this Agreement without
         limitation. In connection with the engagement of Big Sky hereunder, the
         Company   has   entered   into  a  separate   letter   agreement   (the
         "Indemnification  Agreement"),  dated as of the date hereof,  providing
         for the  indemnification  of Big Sky and certain related parties by the
         Company.

Relationship

7.       In the  performance  of its  obligations  hereunder Big Sky shall be an
         independent  contractor  of the  Company.  Big Sky  shall  perform  the
         services  enumerated  herein  according to its own means and methods of
         work and shall not be subject  to the  control  or  supervision  of the
         Company.  The Company acknowledges that nothing in this Agreement shall
         be construed  to require Big Sky to provide  services to the Company at
         any specific time or in any specific place or manner.

                                        2
                                                                    EXHIBIT 10.1
<PAGE>
Miscellaneous

8.       This Agreement and the Indemnification  Agreement constitute the entire
         agreement  between us with respect to the subject matter  hereof.  This
         Agreement  and  Indemnification  Agreement  shall  be  governed  by and
         construed  in  accordance  with the  laws of the  Province  of  British
         Columbia and the parties  hereto  irrevocably  attorn to the  exclusive
         jurisdiction of the Courts thereof and the Courts of Appeal  therefrom.
         Should suit be brought to enforce this Agreement or the Indemnification
         Agreement,  the prevailing  party shall be entitled to recover from the
         other reimbursement for reasonable attorneys' fees.

9.       No waiver of any of the provisions of this Agreement shall be deemed or
         shall  constitute a waiver of any other provision  hereof and no waiver
         shall constitute a continuing waiver. No waiver shall be binding unless
         written  notice  thereof is delivered by the party making the waiver to
         the other party.

10.      The offer  contained  herein will expire and be of no further  force or
         effect  unless  accepted  in writing  prior to the close of business on
         March 30th, 2002. .

Please confirm that the foregoing  correctly sets forth our agreement by signing
and returning to us the enclosed  duplicate copy of this Agreement together with
the  Indemnification  Agreement.  We look forward to working with you and to the
successful conclusion of this engagement.

                                                     Yours very truly,

                                                     Big Sky Management Ltd.

                                                     /s/ Eric Boehnke
                                                     Eric Boehnke
                                                     President

Accepted and Agreed to as of
the 25th day of March, 2002.

Stratabid.com, Inc.

/s/ Derek Wasson

Derek Wasson
President

                                        3
                                                                    EXHIBIT 10.1<PAGE>

                                                                    Exhibit 10.8

March 18, 1996

Marc Lanser, M.D.
Boston Life Sciences
Reservoir Place
1601 Trapelo Road
Waltham, MA 02154

RE: License Agreement Dated 3/15/93
Amendment to Add Patent Application to Appendix B

Dear Marc,

In accordance with Paragraph 8.3 of the Sponsored Research Agreement between
Procell Pharmaceuticals, Inc. and Children's Medical Center Corporation dated
3/15/93, the Appendix B of the License Agreement between the same parties and of
even date is hereby amended to include the following patent application:

CMCC 518 "Pharmaceutical Compositions Comprising Troponin Subunits, Fragments
and Analogs Thereof and Methods of Their Use to Inhibit Angiogenesis" by Marsha
A. Moses, Robert S. Langer, Dimitri Weidershain, Inmin Wu, and Arthus Sytkowski,
filed February 16, 1996.

Sincerely,

/s/ William New
------------------------------
William New
Vice President for Research Administration

Agreed for ProCell Pharmaceuticals, Inc.

/s/ Marc Lanser
------------------------------
Marc Lanser<PAGE>

                                                                   Exhibit 10.11

                                LICENSE AGREEMENT

                                     BETWEEN

                    PRESIDENT AND FELLOWS OF HARVARD COLLEGE

                                       AND

                            BOSTON LIFE SCIENCES INC.

--------------------------------------------------------------------------------

                        EFFECTIVE DATE is, March 15, 2000

                          Re: Harvard Case No. 1615-99
              "Imaging the Dopamine Transporter to Determine AD-HD"

   In consideration of the mutual promises and covenants set forth below, the
parties hereto agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

   As used in this Agreement, the following terms shall have the following
meanings:

1.1  AFFILIATE: any company, corporation, or business in which LICENSEE owns or
     controls at least fifty percent (50%) of the voting stock or other
     ownership. Unless otherwise specified, the term LICENSEE includes
     AFFILIATES.

1.2  BIOLOGICAL MATERIALS: the materials supplied by HARVARD. (identified in
     Appendix B) together with any progeny, mutants, or derivatives thereof
     supplied by HARVARD or created by LICENSEE.

1.3  FIELD: Detection and Treatment of Attention Deficit Hyperactivity Disorder

1.4  GENERAL: The General Hospital Corporation, a nonprofit Massachusetts
     corporation doing business as Massachusetts General Hospital, and having
     offices at the Office of Corporate Sponsored Research and Licensing,
     Massachusetts General Hospital, Bldg. 149, 13th Street, Suite 1101,
     Charlestown, MA 02129.

1.5  HARVARD: President and Fellows of Harvard College, a nonprofit
     Massachusetts educational corporation having offices at the Office of
     Technology Licensing, Harvard Medical School, Building A - Room 414, 25
     Shattuck Street, Boston, Massachusetts 02115.

                                        1

<PAGE>

1.6  LICENSED PROCESSES: the processes covered by PATENT RIGHTS or processes
     utilizing BIOLOGICAL MATERIALS or some portion thereof.

1.7  LICENSED PRODUCTS: products covered by PATENT RIGHTS or products made or
     services provided in accordance with or by means of LICENSED PROCESSES or
     products made or services provided utilizing BIOLOGICAL MATERIALS or
     incorporating some portion of BIOLOGICAL MATERIALS.

1.8  LICENSEE: Boston Life Sciences Inc., a corporation organized under the laws
     of Massachusetts having its principal offices at 137 Newbury St., 8th
     Floor, Boston, MA 02116.

1.9  ORGANIX: Organix Inc., a corporation organized under the laws of
     Massachusetts having its principal offices at 240 Salem Street, Woburn, MA,
     01801.

1.10 NET SALES: the amount billed, invoiced, or received (whichever occurs
     first) for sales, leases, or other transfers of LICENSED PRODUCTS, less:

     (a)  customary trade, quantity or cash discounts and non-affiliated
          brokers' or agents' commissions actually allowed and taken;

     (b)  amounts repaid or credited by reason of rejection or return; and

     (c)  to the extent separately stated on purchase orders, invoices, or other
          documents of sale, taxes levied on and/or other governmental charges
          made as to production, sale, transportation, delivery or use and paid
          by or on behalf of LICENSEE or sublicensees;

     (d)  reasonable charges for delivery or transportation provided by third
          parties, if separately stated.

   NET SALES also includes the fair market value of any non-cash consideration
   received by LICENSEE or sublicensees for the sale, lease, or transfer of
   LICENSED PRODUCTS.

1.11 NON-COMMERCIAL RESEARCH PURPOSES: use of PATENT RIGHTS and/or BIOLOGICAL
     MATERIALS for academic research or other not-for-profit scholarly purposes
     which are undertaken at a non-profit or governmental institution that does
     not use the PATENT RIGHTS and/or BIOLOGICAL MATERIALS in the production or
     manufacture of products for sale or the performance of services for a fee.

1.12 NON-COMMERCIAL CLINICAL PURPOSES: use of PATENT RIGHTS and/or BIOLOGICAL
     MATERIALS for any purpose related to patient care at GENERAL, HARVARD, or
     any not-for-profit hospital affiliated with GENERAL that does not use the
     PATENT RIGHTS and/or BIOLOGICAL MATERIALS in the production or manufacture
     of products for sale.

1.13 NON-ROYALTY SUBLICENSE INCOME: Sublicense issue fees, sublicense
     maintenance fees, sublicense milestone payments, and similar non-royalty
     payments

                                        2

<PAGE>

     made by sublicensees to LICENSEE on account of sublicenses pursuant to this
     Agreement.

1.14 OTHER HARVARD TECHNOLOGIES: Technology licensed by HARVARD to LICENSEE
     under existing license agreements dated November 16, 1992 (Harvard Case No.
     788-91), December 10, 1993 (Harvard Case No. 919-93), and October 15, 1996
     (Harvard Case No. 1194-95) the particular use of which falls under PATENT
     RIGHTS in the FIELD.

1.15 PATENT RIGHTS: United States provisional application Serial No. 60/141,540
     filed June 28, 1999, the inventions described and claimed therein, and any
     divisions, continuations, continuations-in-part to the extent the claims
     are directed to subject matter specifically described in provisional
     application 60/141,540 and are dominated by the claims of the existing
     PATENT RIGHTS, patents issuing thereon or reissues thereof, and any and all
     foreign patents and patent applications corresponding thereto, all to the
     extent owned or controlled by HARVARD.

1.16 TERRITORY: Worldwide

1.17 The terms "Public Law 96-517" and "Public Law 98-620" include all
     amendments to those statutes.

1.18 The terms "sold" and "sell" include, without limitation, leases and other
     transfers and similar transactions.

                                   ARTICLE II

                                 REPRESENTATIONS

2.1  HARVARD is owner by assignment from Dr. Bertha Madras; and ORGANIX is owner
     by assignment from Dr. Peter Meltzer; and GENERAL is owner by assignment
     from Dr. Alan Fischman, of their entire right, title and interest in United
     States Provisional Patent Application Serial No. 60/141,540, filed June 28,
     1999 entitled "Imaging the Dopamine Transporter to Determine AD-HD", (H.U.
     Case #1615-99), in the foreign patent applications corresponding thereto,
     and in the inventions described and claimed therein.

2.2  In an Invention and License Agreement effective February 15, 2000, GENERAL
     and ORGANIX have appointed HARVARD their sole and exclusive agent to
     license United States Provisional Patent Application Serial No. 60/141,540
     on their behalf. HARVARD therefore has the authority to issue licenses
     under PATENT RIGHTS.

2.3  HARVARD is committed to the policy that ideas or creative works produced at
     HARVARD should be used for the greatest possible public benefit, and
     believes that every reasonable incentive should be provided for the prompt
     introduction of such ideas into public use, all in a manner consistent with
     the public interest.

2.4  HARVARD and LICENSEE have entered in and are parties to existing license
     agreements dated November 16, 1992 (Harvard Case No. 788-91), December 10,
     1993

                                        3

<PAGE>

     (Harvard Case No. 919-93), and October 15, 1996 (Harvard Case No. 1194-95)
     which confers to LICENSEE commercial rights to technology that may used in
     conjunction with subject matter of PATENT RIGHTS.

2.5  LICENSEE is prepared and intends to diligently develop the invention and to
     bring products to market which are subject to this Agreement.

2.6  LICENSEE is desirous of obtaining an exclusive license in the TERRITORY in
     order to practice the above-referenced invention covered by PATENT RIGHTS
     in the United States and in certain foreign countries, and to manufacture,
     use and sell in the commercial market the products made in accordance
     therewith, and HARVARD is desirous of granting such a license to LICENSEE
     in accordance with the terms of this Agreement.

                                  ARTICLE III

                                 GRANT OF RIGHTS

3.1  HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the
     terms and conditions hereof, in the TERRITORY and in the FIELD:

     (a)  an exclusive commercial license under PATENT RIGHTS, and

     (b)  a license to use BIOLOGICAL MATERIALS

     to make and have made, to use and have used, to sell and have sold the
     LICENSED PRODUCTS, and to practice the LICENSED PROCESSES, for the life of
     the PATENT RIGHTS. Such licenses shall include the right to grant
     sublicenses, subject to HARVARD's approval, which approval shall not be
     unreasonably withheld. In order to provide LICENSEE with commercial
     exclusivity for so long as the license under PATENT RIGHTS remains
     exclusive, HARVARD agrees that it will not grant licenses under PATENT
     RIGHTS to others except as required by HARVARD's obligations in paragraph
     3.2(a) or as permitted in paragraph 3.2(b) and that it will not provide
     BIOLOGICAL MATERIALS to others for any commercial purpose.

3.2  The granting and exercise of this license is subject to the following
     conditions:

     (a)  HARVARD's "Statement of Policy in Regard to Inventions, Patents and
          Copyrights," dated August 10, 1998, Public Law 96-517, Public Law
          98-620, and HARVARD's obligations under agreements with other sponsors
          of research. Any right granted in this Agreement greater than that
          permitted under Public Law 96-517, or Public Law 98-620, shall be
          subject to modification as may be required to conform to the
          provisions of those statutes.

     (b)  HARVARD, ORGANIX, and GENERAL reserve the right to

          (i)   make, use, and provide the BIOLOGICAL MATERIALS to others on a
                non-exclusive basis, and grant others non-exclusive licenses to
                make and

                                        4

<PAGE>

                use the BIOLOGICAL MATERIALS, all for NON-COMMERCIAL RESEARCH
                PURPOSES; and

          (ii)  make and use, and grant to others non-exclusive licenses to make
                and use for NON-COMMERCIAL RESEARCH PURPOSES the subject matter
                described and claimed in PATENT RIGHTS; and

          (iii) to use the subject matter described and claimed in PATENT RIGHTS
                for NON-COMMERCIAL CLINICAL PURPOSES.

     (c)  LICENSEE shall use diligent efforts to effect introduction of the
          LICENSED PRODUCTS into the commercial market as soon as practicable,
          consistent with sound and reasonable business practice and judgment;
          thereafter, until the expiration of this Agreement, LICENSEE shall
          endeavor to keep LICENSED PRODUCTS reasonably available to the public.

     (d)  At any time after three (3) years from the effective date of this
          Agreement, HARVARD may terminate or render this license non-exclusive
          if, in HARVARD's reasonable judgment, the Progress Reports furnished
          by LICENSEE do not demonstrate that LICENSEE:

          (i)   has put the licensed subject matter into commercial use in the
                country or countries hereby licensed, directly or through a
                sublicense, and is keeping the licensed subject matter
                reasonably available to the public, or

          (ii)  is engaged in research, development, manufacturing, marketing or
                sublicensing activity appropriate to achieving 3.2(d)(i).

Additional, specific performance milestones:

     (e)  In all sublicenses granted by LICENSEE hereunder, LICENSEE shall
          include a requirement that the sublicensee use its best efforts to
          bring the subject matter of the sublicense into commercial use as
          quickly as is reasonably possible. LICENSEE shall further provide in
          such sublicenses. that, such sublicenses are subject and subordinate
          to the terms and conditions of this Agreement, except: (i) the
          sublicensee may not further sublicense; and (ii) the rate of royalty
          on NET SALES paid by the sublicensee to the LICENSEE. Copies of all
          sublicense agreements shall be provided promptly to HARVARD.

     (f)  If LICENSEE is unable or unwilling to grant sublicenses, either as
          suggested by HARVARD or by a potential sublicensee or otherwise, then
          HARVARD may directly license such potential sublicensee unless, in
          Harvard's reasonable judgment, such license would be contrary to sound
          and reasonable business practice and the granting of such license
          would not materially increase the availability to the public of
          LICENSED PRODUCTS.

     (g)  A license in any other territory or field of use in addition to the
          TERRITORY and/or FIELD shall be the subject of a separate agreement
          and shall require

                                        5

<PAGE>

          LICENSEE's submission of evidence, satisfactory to HARVARD,
          demonstrating LICENSEE's willingness and ability to develop and
          commercialize in such other territory and/or field of use the kinds of
          products or processes likely to be encompassed in such other territory
          and/or field.

     (h)  During the period of exclusivity of this license in the United States,
          LICENSEE shall cause any LICENSED PRODUCT produced for sale in the
          United States to be manufactured substantially in the United States.

3.3  All rights reserved to the United States Government and others under Public
     Law 96-517, and Public Law 98-620, shall remain and shall in no way be
     affected by this Agreement.

                                   ARTICLE IV

                                    ROYALTIES

4.1  LICENSEE shall pay to HARVARD a non-refundable license royalty fee in the
     sum of One Hundred Thousand Dollars ($100,000) within ten (10) days of the
     Effective Date of this Agreement, and the sum of Fifty Thousand Dollars
     ($50,000) upon issuance of the first U.S. patent in PATENT RIGHTS. The
     first one hundred thousand dollars of the license execution fee is fully
     creditable toward milestone payments for filing a new or supplemental IND
     (as appropriate).

4.2  (a)  LICENSEE shall pay to HARVARD during the term of this Agreement:

          (i)  a royalty of one percent (1%) of NET SALES by LICENSEE and
               sublicensees on LICENSED PRODUCTS which are OTHER HARVARD
               TECHNOLOGIES;

          (ii) a royalty of five percent (5%) of NET SALES by LICENSEE and
               sublicensees on all LICENSED PRODUCTS which are not OTHER HARVARD
               TECHNOLOGIES.

     (b)  In the case of sublicenses, LICENSEE shall also pay to HARVARD:

          (i)  a royalty of five percent (5%) of NON-ROYALTY SUBLICENSE INCOME
               derived from OTHER HARVARD TECHNOLOGIES;

          (ii) a royalty of twenty-five percent (25%) of NON-ROYALTY SUBLICENSE
               INCOME on all LICENSED PRODUCTS which are not OTHER HARVARD
               TECHNOLOGIES.

     (c)  If the license pursuant to this Agreement is converted to a
          non-exclusive one and if other non-exclusive licenses in the same
          field and territory are granted, the above royalties shall not exceed
          the royalty rate to be paid by other licensees in the same field and
          territory during the term of the non-exclusive license.

                                        6

<PAGE>

     (d)  On sales between LICENSEE and its AFFILIATES or sublicensees for
          resale, the royalty shall be paid on the NET SALES of the AFFILIATE or
          sublicensee.

4.3  LICENSEE shall pay to HARVARD the following amounts in license milestone
     payments for each LICENSED PRODUCTS:

     Upon filing a new or supplemental IND (as appropriate)             $100,000
     Upon successful completion of a Phase II or Phase II/III
           clinical trial (as appropriate)                              $250,000
     Upon NDA Approval                                                  $500,000

     Milestone fees paid to HARVARD on OTHER HARVARD TECHNOLOGIES achieved in
     the FIELD are fully creditable toward these fees.

4.4  No later than January 1 of each calendar year after the effective date of
     this Agreement, LICENSEE shall pay to HARVARD the following non-refundable
     license maintenance royalty and/or advance on royalties. Such payments may
     be credited against running royalties due for that calendar year and
     Royalty Reports shall reflect such a credit.

     ---------------------------------------------------
     January 1, 2001               $15,000
     ---------------------------------------------------
     each year thereafter          $25,000
     ---------------------------------------------------

4.5  There shall be a fee of $10,000 for each continuation-in-part application
     (CIP) added under Patent Rights pursuant to this Agreement. LICENSEE shall
     have 60 days following notice from HARVARD of the filing of such CIP's to
     determine if they wish to pay such fees and include the CIP's under the
     Agreement.

                                   ARTICLE V

                                   REPORTING

5.1  Prior to signing this Agreement, LICENSEE has provided to HARVARD a written
     research and development plan under which LICENSEE intends to bring the
     subject matter of the licenses granted hereunder into commercial use upon
     execution of this Agreement.

5.2  No later than sixty (60) days after June 30 of each calendar year, LICENSEE
     shall provide to HARVARD a written annual Progress Report describing
     progress on research and development, regulatory approvals, manufacturing,
     sublicensing, marketing and sales during the most recent twelve (12) month
     period ending June 30 and plans for the forthcoming year. If multiple
     technologies are covered by the license granted hereunder, the Progress
     Report shall provide the information set forth above for each technology.
     If progress differs from that anticipated in the plan required under
     Paragraph 5.1, LICENSEE shall explain the reasons for the difference and
     propose a modified research and development plan for HARVARD's review and
     approval. LICENSEE shall also provide any reasonable additional data
     HARVARD requires to evaluate LICENSEE's performance.

                                        7

<PAGE>

5.3  LICENSEE shall report to HARVARD the date of first sale of LICENSED
     PRODUCTS (or results of LICENSED PROCESSES) in each country within thirty
     (30) days of occurrence.

5.4  (a)   LICENSEE shall submit to HARVARD within sixty (60) days after each
     calendar half year ending June 30 and December 31, a Royalty Report setting
     forth for such half year at least the following information:

     (i)   the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES and
           sublicensees in each country;

     (ii)  total billings for such LICENSED PRODUCTS;

     (iii) an accounting for all LICENSED PROCESSES used or sold;

     (iv)  deductions applicable to determine the NET SALES thereof;

     (v)   the amount of NON-ROYALTY SUBLICENSE INCOME received by LICENSEE; and

     (vi)  the amount of royalty due thereon, or, if no royalties are due to
           HARVARD for any reporting period, the statement that no royalties are
           due.

     Such report shall be certified as correct by an officer of LICENSEE and
     shall include a detailed listing of all deductions from royalties.

     (b)   LICENSEE shall pay to HARVARD with each such Royalty Report the
           amount of royalty due with respect to such half year. If multiple
           technologies are covered by the license granted hereunder, LICENSEE
           shall specify which PATENT RIGHTS and BIOLOGICAL MATERIALS are
           utilized for each LICENSED PRODUCT and LICENSED PROCESS included in
           the Royalty Report.

     (c)   All payments due hereunder shall be deemed received when funds are
           credited to Harvard's bank account and shall be payable by check or
           wire transfer in United States dollars. Conversion of foreign
           currency to U.S. dollars shall be made at the conversion rate
           existing in the United States (as reported in the New York Times or
           the Wall Street Journal) on the last working day of each royalty
           period. No transfer, exchange, collection or other charges shall be
           deducted from such payments.

     (d)   All such reports shall be maintained in confidence by HARVARD except
           as required by law; however, HARVARD may include in its usual reports
           annual amounts of royalties paid.

     (e)   Late payments shall be subject to a charge of one and one half
           percent (1 1/2%) per month, or $250, whichever is greater.

                                        8

<PAGE>

                                   ARTICLE VI

                                 RECORD KEEPING

6.1  LICENSEE shall keep, and shall require its AFFILIATES and sublicensees to
     keep, accurate records (together with supporting documentation) of LICENSED
     PRODUCTS made, used or sold under this Agreement, appropriate to determine
     the amount of royalties due to HARVARD hereunder. Such records shall be
     retained for at least three (3) years following the end of the reporting
     period to which they relate. They shall be available during normal business
     hours for examination by an accountant selected by HARVARD, for the sole
     purpose of verifying reports and payments hereunder. In conducting
     examinations pursuant to this paragraph, HARVARD's accountant shall have
     access to all records which HARVARD reasonably believes to be relevant to
     the calculation of royalties under Article IV.

6.2  HARVARD's accountant shall not disclose to HARVARD any information other
     than information relating to the accuracy of reports and payments made
     hereunder.

6.3  Such examination by HARVARD's accountant shall be at HARVARD's expense,
     except that if such examination shows an underreporting or underpayment in
     excess of five percent (5%) for any twelve (12) month period, then LICENSEE
     shall pay the cost of such examination as well as any additional sum that
     would have been payable to HARVARD had the LICENSEE reported correctly,
     plus interest on said sum at the rate of one and one half per cent (1 1/2%)
     per month.

                                   ARTICLE VII

               DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

7.1  Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for all
     reasonable expenses HARVARD has incurred for the preparation, filing,
     prosecution and maintenance of PATENT RIGHTS. Thereafter, LICENSEE shall
     reimburse HARVARD for all such future expenses upon receipt of invoices
     from HARVARD. Late payment of these invoices shall be subject to interest
     charges of one and one-half percent (1 1/2%) per month. HARVARD shall, in
     its sole discretion, be responsible for the preparation, filing,
     prosecution and maintenance of any and all patent applications and patents
     included in PATENT RIGHTS. HARVARD shall consult with LICENSEE as to the
     preparation, filing, prosecution and maintenance of such patent
     applications and patents and shall furnish to LICENSEE copies of documents
     relevant to any such preparation, filing, prosecution or maintenance.

7.2  HARVARD and LICENSEE shall cooperate fully in the preparation, filing,
     prosecution and maintenance of PATENT RIGHTS and of all patents and patent
     applications licensed to LICENSEE hereunder, executing all papers and
     instruments or requiring members of HARVARD to execute such papers and
     instruments so as to enable HARVARD to apply for, to prosecute and to
     maintain patent applications and patents in HARVARD's name in any country.
     Each party shall provide to the other prompt notice

                                        9

<PAGE>

     as to all matters which come to its attention and which may affect the
     preparation, filing, prosecution or maintenance of any such patent
     applications or patents.

7.3  LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty
     (60) days written notice to HARVARD. Such notice shall not relieve LICENSEE
     from responsibility to reimburse HARVARD for patent-related expenses
     incurred prior to the expiration of the (60)-day notice period (or such
     longer period specified in LICENSEE's notice).

                                  ARTICLE VIII

                                  INFRINGEMENT

8.1  With respect to any PATENT RIGHTS that are exclusively licensed to LICENSEE
     pursuant to this Agreement, LICENSEE shall have the right to prosecute in
     its own name and at its own expense any infringement of such patent, so
     long as such license is exclusive at the time of the commencement of such
     action. HARVARD agrees to notify LICENSEE promptly of each infringement of
     such patents of which HARVARD is or becomes aware. Before LICENSEE
     commences an action with respect to any infringement of such patents,
     LICENSEE shall give careful consideration to the views of HARVARD and to
     potential effects on the public interest in making its decision whether or
     not to sue.

8.2  (a)  If LICENSEE elects to commence an action as described above, Harvard
          may, to the extent permitted by law, elect to join as a party in that
          action. Regardless of whether HARVARD elects to join as a party,
          HARVARD shall cooperate fully with LICENSEE in connection with any
          such action.

     (b)  If HARVARD elects to join as a party pursuant to subparagraph (a),
          HARVARD shall jointly control the action with LICENSEE.

     (c)  LICENSEE shall reimburse HARVARD for any costs HARVARD incurs,
          including reasonable attorneys' fees, as part of an action brought by
          LICENSEE, irrespective of whether HARVARD becomes a co-plaintiff.

8.3  If LICENSEE elects to commence an action as described above, LICENSEE may
     deduct from its royalty payments to HARVARD with respect to the patent(s)
     subject to suit an amount not exceeding fifty percent (50%) of LICENSEE's
     expenses and costs of such action, including reasonable attorneys' fees;
     provided, however, that such reduction shall not exceed fifty percent (50%)
     of the total royalty due to HARVARD with respect to the patent(s) subject
     to suit for each calendar year. If such fifty percent (50%) of LICENSEE's
     expenses and costs exceeds the amount of royalties deducted by LICENSEE for
     any calendar year, LICENSEE may to that extent reduce the royalties due to
     HARVARD from LICENSEE in succeeding calendar years, but never by more than
     fifty percent (50%) of the total royalty due in any one year with respect
     to the patent(s) subject to suit.

                                       10

<PAGE>

8.4  No settlement, consent judgment or other voluntary final disposition of the
     suit may be entered into without the prior written consent of -HARVARD,
     which consent shall not be unreasonably withheld.

8.5  Recoveries or reimbursements from actions commenced pursuant to this
     Article shall first be applied to reimburse LICENSEE and HARVARD for
     litigation costs not paid from royalties and then to reimburse HARVARD for
     royalties deducted by LICENSEE pursuant to paragraph 8.3. LICENSEE and
     HARVARD shall share any remaining recoveries or reimbursements equally.

8.6  If LICENSEE elects not to exercise its right to prosecute an infringement
     of the PATENT RIGHTS pursuant to this Article, HARVARD may do so at its own
     expense, controlling such action and retaining all recoveries therefrom.
     LICENSEE shall cooperate fully with HARVARD in connection with any such
     action.

8.7  Without limiting the generality of paragraph 8.6, HARVARD may, at its
     election and by notice to LICENSEE, establish a time limit of sixty (60)
     days for LICENSEE to decide whether to prosecute any infringement of which
     HARVARD is or becomes aware. If, by the end of such sixty (60)-day period,
     LICENSEE has not commenced such an action, HARVARD may prosecute such an
     infringement at its own expense, controlling such action and retaining all
     recoveries therefrom. With respect to any such infringement action
     prosecuted by HARVARD in good faith, LICENSEE shall pay over to Harvard any
     payments (whether or not designated as "royalties") made by the alleged
     infringer to LICENSEE under any existing or future sublicense authorizing
     LICENSED PRODUCTS, up to the amount of HARVARD's unreimbursed litigation
     expenses (including, but not limited to, reasonable attorneys' fees).

8.8  If a declaratory judgment action is brought naming LICENSEE as a defendant
     and alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to
     take over the sole defense of the action at its own expense. LICENSEE shall
     cooperate fully with HARVARD in connection with any such action.

                                   ARTICLE IX

                            TERMINATION OF AGREEMENT

9.1  This Agreement, unless terminated as provided herein, shall remain in
     effect until the last patent or patent application in PATENT RIGHTS has
     expired or been abandoned.

9.2  HARVARD may terminate this Agreement as follows:

     (a)  If LICENSEE does not make a payment due hereunder and fails to cure
          such non-payment (including the payment of interest in accordance with
          paragraph 54(e)) within forty-five (45) days after the date of notice
          in writing of such non-payment by HARVARD.

     (b)  If LICENSEE defaults in its obligations under paragraph 10.4(c) and
          (d) to procure and maintain insurance.

                                       11

<PAGE>

     (c)  If, at any time after three years from the date of this Agreement,
          HARVARD determines that the Agreement should be terminated pursuant to
          paragraph 3.2(d).

     (d)  If LICENSEE shall become insolvent, shall make an assignment for the
          benefit of creditors, or shall have a petition in bankruptcy filed for
          or against it. Such termination shall be effective immediately upon
          HARVARD giving written to LICENSEE.

     (e)  If an examination by Harvard's accountant pursuant to Article VI shows
          an underreporting or underpayment by LICENSEE in excess of 20% for any
          twelve (12) month period.

     (f)  If LICENSEE is convicted of a felony relating to the manufacture, use,
          or sale of LICENSED PRODUCTS.

     (g)  Except as provided in subparagraphs (a), (b), (c), (d), (e) and (f)
          above, if LICENSEE defaults in the performance of any obligations
          under this Agreement and the default has not been remedied within
          ninety (90) days after the date of notice in writing of such default
          by HARVARD.

9.3  LICENSEE shall provide, in all sublicenses granted by it under this
     Agreement, that LICENSEE's interest in such sublicenses shall at HARVARD's
     option terminate or be assigned to HARVARD upon termination of this
     Agreement.

9.4  LICENSEE may terminate this Agreement by giving ninety (90) days advance
     written notice of termination to HARVARD and paying a termination fee of
     twenty thousand dollars ($20,000). Upon termination, LICENSEE shall submit
     a final Royalty Report to HARVARD and any royalty payments and unreimbursed
     patent expenses invoiced by HARVARD shall become immediately payable.

9.5  Upon termination pursuant to Paragraph 9.2, whether by HARVARD or by
     LICENSEE, LICENSEE shall cease all use of the BIOLOGICAL MATERIALS and
     shall, upon request, return or destroy (at Harvard's option) all BIOLOGICAL
     MATERIALS under its control or in its possession.

9.6  Paragraphs 6.1, 6.2, 6.3, 7.1, 8.5, 9.4, 9.5, 9.6, 10.2, 10.4, 10.5, 10.8
     and 10.9 of this Agreement shall survive termination.

                                    ARTICLE X

                                     GENERAL

10.1 HARVARD does not warrant the validity of the PATENT RIGHTS licensed
     hereunder and makes no representations whatsoever with regard to the scope
     of the licensed PATENT RIGHTS or that such PATENT RIGHTS or BIOLOGICAL
     MATERIALS may be exploited by LICENSEE, an AFFILIATE, or sublicensee
     without infringing other patents.

                                       12

<PAGE>

10.2 HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND
     MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
     ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS, BIOLOGICAL MATERIALS, OR
     INFORMATION SUPPLIED BY HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS
     CONTEMPLATED BY THIS AGREEMENT. Further HARVARD has made no investigation
     and makes no representation that the BIOLOGICAL MATERIALS supplied by it or
     the methods used in making or using such materials are free from liability
     for patent infringement.

10.3 LICENSEE shall not distribute or release the BIOLOGICAL MATERIALS to others
     except to further the purposes of this Agreement. LICENSEE shall protect
     the BIOLOGICAL MATERIALS at least as well as it protects its own valuable
     tangible personal property and shall take measures to protect the
     BIOLOGICAL MATERIALS from any claims by third parties including creditors
     and trustees in bankruptcy.

10.4 (a)  LICENSEE shall indemnify, defend and hold harmless HARVARD, ORGANIX,
          GENERAL and their current or former directors, governing board
          members, trustees, officers, faculty, medical and professional staff,
          employees, students, and agents and their respective successors, heirs
          and assigns (collectively, the "Indemnitees"), against any liability,
          damage, loss or expenses (including reasonable attorneys' fees and
          expenses of litigation) incurred by or imposed upon the Indemnitees or
          any of them in connection with any claims, suits, actions, demands or
          judgments arising out of any theory of product liability (including,
          but not limited to, actions in the form of tort, warranty, or strict
          liability) concerning any product, process or service made, used or
          sold pursuant to any right or license granted under this Agreement.

     (b)  LICENSEE shall, at its own expense, provide attorneys reasonably
          acceptable to HARVARD to defend against any actions brought or filed
          against any Indemnitee hereunder with respect to the subject of
          indemnity contained herein, whether or not such actions are rightfully
          brought.

     (c)  Beginning at the time any such product, process or service is being
          commercially distributed or sold (other than for the purpose of
          obtaining regulatory approvals) by LICENSEE or by a sublicensee,
          AFFILIATE or agent of LICENSEE, LICENSEE shall, at its sole cost and
          expense, procure and maintain commercial general liability insurance
          in amounts not less than $2,000,000 per incident and $2,000,000 annual
          aggregate and naming the Indemnitees as additional insureds. During
          clinical trials of any such product, process or service, LICENSEE
          shall, at its sole cost and expense, procure and maintain commercial
          general liability insurance in such equal or lesser amount as HARVARD
          shall require, naming the Indemnitees as additional insureds. Such
          commercial general liability insurance shall provide (i) product
          liability coverage and (ii) broad form contractual liability coverage
          for LICENSEE's indemnification under this Agreement. If LICENSEE
          elects to self-insure all or part of the limits described above
          (including deductibles or retentions which are in excess of $250,000
          annual aggregate) such self

                                       13

<PAGE>

          insurance program must be acceptable to HARVARD and the Risk
          Management Foundation of the Harvard Medical Institutions, Inc. in
          their sole discretion. The minimum amounts of insurance coverage
          required shall not be construed to create a limit of LICENSEE's
          liability with respect to its indemnification under this Agreement.

     (d)  LICENSEE shall provide HARVARD with written evidence of such insurance
          upon request of HARVARD. LICENSEE shall provide HARVARD with written
          notice at least fifteen (15) days prior to the cancellation,
          non-renewal or material change in such insurance; if LICENSEE does not
          obtain replacement insurance providing comparable coverage within such
          fifteen (15) day period, HARVARD shall have the right to terminate
          this Agreement effective at the end of such fifteen (15) day period
          without notice or any additional waiting periods.

     (d)  LICENSEE shall maintain such commercial general liability insurance
          beyond the expiration or termination of this Agreement during (1) the
          period that any product, process, or service, relating to, or
          developed pursuant to, this Agreement is being commercially
          distributed or sold by LICENSEE or by a sublicensee, AFFILIATE or
          agent of LICENSEE and (ii) a reasonable period after the period
          referred to in (e)(i) above which in no event shall be less than
          fifteen (15) years.

10.5 LICENSEE shall not use HARVARD's, ORGANIX's, or GENERAL's name or insignia,
     or any adaptation of them, or the name of any of HARVARD's, ORGANIX's or
     GENERAL's inventors or other investigators in any advertising, promotional
     or sales literature without the prior written approval of HARVARD, ORGANIX,
     or GENERAL, as the case may be.

10.6 Without the prior written approval of HARVARD in each instance, neither
     this Agreement nor the rights granted hereunder shall be transferred or
     assigned in whole or in part by LICENSEE to any person whether voluntarily
     or involuntarily, by operation of law or otherwise. This Agreement shall be
     binding upon the respective successors, legal representatives and assignees
     of HARVARD and LICENSEE.

10.7 The interpretation and application of the provisions of this Agreement
     shall be governed by the laws of the Commonwealth of Massachusetts.

10.8 LICENSEE shall comply with all applicable laws and regulations. In
     particular, it is understood and acknowledged that the transfer of certain
     commodities and technical data is subject to United States laws and
     regulations controlling the export of such commodities and technical data,
     including all Export Administration Regulations of the United States
     Department of Commerce. These laws and regulations among other things,
     prohibit or require a license for the export of certain types of technical
     data to certain specified countries. LICENSEE hereby agrees and gives
     written assurance that it will comply with all United States laws and
     regulations controlling the export of commodities and technical data, that
     it will be solely responsible for any violation of such by LICENSEE or its
     AFFILIATES or sublicensees, and that it will defend and hold

                                       14

<PAGE>

      HARVARD harmless in the event of any legal action of any nature occasioned
      by such violation.

10.9  LICENSEE agrees (i) to obtain all regulatory approvals required for the
      manufacture and sale of LICENSED PRODUCTS and LICENSED PROCESSES and (ii)
      to utilize appropriate patent marking on such LICENSED PRODUCTS. LICENSEE
      also agrees to register or record this Agreement as is required by law or
      regulation in any country where the license is in effect.

10.10 Any notices to be given hereunder shall be sufficient if signed by the
      party (or party's attorney) giving same and either (a) delivered in
      person, or (b) mailed certified mail return receipt requested, or (c)
      faxed to other party if the sender has evidence of successful transmission
      and if the sender promptly sends the original by ordinary mail, in any
      event to the following addresses:

      If to LICENSEE:

             Boston Life Sciences Inc.
             137 Newbury Street, 8th Floor
             Boston, MA 02116
             Fax No.: (617) 425-0996

      If to HARVARD to:

             Office of Technology Licensing
             Harvard Medical School
             Building A - Room 414
             25 Shattuck Street
             Boston, MA 02115
             Fax No.: (617) 432-2788

      with copies to:

             Office for Technology and Trademark Licensing
             Harvard University
             1350 Massachusetts Avenue, Suite 727
             Cambridge, MA 02138
             Fax No.: (617) 495-9568

      By such notice either party may change their address for future notices.

      Notices delivered in person shall be deemed given on the date delivered.
      Notices sent by fax shall be deemed given on the date faxed. Notices
      mailed shall be deemed given on the date postmarked on the envelope.

10.11 Should a court of competent jurisdiction later hold any provision of this
      Agreement to be invalid, illegal, or unenforceable, and such holding is
      not reversed on appeal, it shall be considered severed from this
      Agreement. All other provisions, rights and obligations

                                       15

<PAGE>

      shall continue without regard to the severed provision, provided that the
      remaining provisions of this Agreement are in accordance with the
      intention of the parties.

10.12 In the event of any controversy or claim arising out of or relating to any
      provision of this Agreement or the breach thereof, the parties shall try
      to settle such conflict amicably between themselves. Subject to the
      limitation stated in the final sentence of this section, any such conflict
      which the parties are unable to resolve promptly shall be settled through
      arbitration conducted in accordance with the rules of the American
      Arbitration Association. The demand for arbitration shall be filed within
      a reasonable time after the controversy or claim has arisen, and in no
      event after the date upon which institution of legal proceedings based on
      such controversy or claim would be barred by the applicable statute of
      limitation. Such arbitration shall be held in Boston, Massachusetts. The
      award through arbitration shall` be final and binding. Either party may
      enter any such award in a court having jurisdiction or may make
      application to such court for judicial acceptance of the award and an
      order of enforcement, as the case may be. Notwithstanding the foregoing,
      either party may, without recourse to arbitration, assert against the
      other party a third-party claim or cross-claim in any action brought by a
      third party, to which the subject matter of this Agreement may be
      relevant.

10.13 This Agreement constitutes the entire understanding between the parties
      and neither party shall be obligated by any condition or representation
      other than those expressly stated herein or as may be subsequently agreed
      to by the parties hereto in writing.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
      executed by their duly authorized representatives.

PRESIDENT AND FELLOWS                          LICENSEE
 OF HARVARD COLLEGE

/s/ Jeffrey Labovitz                                   /s/ Marc Lanser
---------------------------                    ---------------------------------
Jeffrey Labovitz, Ph.D., Director                          Signature
Office of Technology Licensing
                                                          Marc Lanser
                                               ---------------------------------
                                                             Name

                                                          Executive VP
                                               ---------------------------------
                                                             Title

                                       16

<PAGE>

Appendix A

The following comprise PATENT RIGHTS:

U.S. Provisional Application Serial No. 60/141,540, filed June 28, 1999 entitled
"Imaging the Dopamine Transporter to Determine AD-HD"

                                       17

<PAGE>

Appendix B

The following comprise BIOLOGICAL MATERIALS:

None

                                       18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]